{"entity":{"id":"nct07080619","kind":"trial","name":"SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers","aka":[],"tldr":"A phase 2 trial of SC-101 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.","summary":"SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers is a phase 2 interventional study registered as NCT07080619 by Tianjin ConjuStar Biologics Co., Ltd., with 120 participants planned, started 2025-08-26. Conditions recorded: TNBC - Triple-Negative Breast Cancer and HR+ Breast Cancer. Interventions recorded: SC-101.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07080619","url":"https://clinicaltrials.gov/study/NCT07080619"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["sc-101"],"companies":["conjustar-biologics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07080619","phase":"2","setting":"A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07080619/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"sc-101","kind":"drug","name":"SC-101","route":"/drugs/sc-101/"}],"company":[{"id":"conjustar-biologics","kind":"company","name":"ConjuStar Biologics","route":"/companies/conjustar-biologics/"}]}}